EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Daphne S. Bakker; Lieneke F.M. Ariens; Barbara Giovannone; Dirk Jan Hijnen; Eveline M. Delemarre; Edward Knol; Stefan Nierkens; Marjolein S. de Bruin-Weller; Judith L. Thijs; Julia Drylewicz

doi:10.1111/all.14492

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Daphne S. Bakker, Lieneke F.M. Ariens, Barbara Giovannone, Dirk Jan Hijnen, Eveline M. Delemarre, Edward Knol, Stefan Nierkens, Marjolein S. de Bruin-Weller, Judith L. Thijs, Julia Drylewicz

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

17 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	3287-3289
Aantal pagina's	3
Tijdschrift	Allergy: European Journal of Allergy and Clinical Immunology
Volume	75
Nummer van het tijdschrift	12
DOI's	https://doi.org/10.1111/all.14492
Status	Gepubliceerd - dec. 2020
Extern gepubliceerd	Ja

Toegang tot document

10.1111/all.14492

Citeer dit

Bakker, D. S., Ariens, L. F. M., Giovannone, B., Hijnen, D. J., Delemarre, E. M., Knol, E., Nierkens, S., de Bruin-Weller, M. S., Thijs, J. L., & Drylewicz, J. (2020). EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy: European Journal of Allergy and Clinical Immunology, 75(12), 3287-3289. https://doi.org/10.1111/all.14492

@article{ab0851b9b29649f0bdfdb45d681839ec,

title = "EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers",

keywords = "atopic dermatitis, biologics, biomarkers",

author = "Bakker, {Daphne S.} and Ariens, {Lieneke F.M.} and Barbara Giovannone and Hijnen, {Dirk Jan} and Delemarre, {Eveline M.} and Edward Knol and Stefan Nierkens and {de Bruin-Weller}, {Marjolein S.} and Thijs, {Judith L.} and Julia Drylewicz",

note = "Funding Information: Dr Bakker reports personal fees from Sanofi Genzyme, outside the submitted work. Dr Hijnen reports grants and personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Incyte, personal fees from Sanofi/Genzyme, grants from Thermo Fisher and personal fees from Pfizer, outside the submitted work. Dr de Bruin‐Weller reports grants as Advisory Board Member/consultant AbbVie, grants as Advisory Board Member/consultant Pfizer, grants as Advisory Board Member/consultant Sanofi Genzyme, grants as Advisory Board Member UCB, grants as Advisory Board Member/consultant Eli Lilly, grants as Advisory Board Member/consultant Regeneron, grants as Advisory Board Member Galderma, grants as PI multicenter studies AbbVie, grants as PI multicenter studies Pfizer, grants as PI multicenter studies Galderma, outside the submitted work. Dr Thijs reports personal fees from Sanofi Genzyme, outside the submitted work. All other authors have nothing to disclose.",

year = "2020",

month = dec,

doi = "10.1111/all.14492",

language = "English",

volume = "75",

pages = "3287--3289",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

Bakker, DS, Ariens, LFM, Giovannone, B, Hijnen, DJ, Delemarre, EM, Knol, E, Nierkens, S, de Bruin-Weller, MS, Thijs, JL & Drylewicz, J 2020, 'EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers', Allergy: European Journal of Allergy and Clinical Immunology, vol. 75, nr. 12, blz. 3287-3289. https://doi.org/10.1111/all.14492

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. / Bakker, Daphne S.; Ariens, Lieneke F.M.; Giovannone, Barbara et al.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Nr. 12, 12.2020, blz. 3287-3289.

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

TY - JOUR

T1 - EASI p-EASI

T2 - Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

AU - Bakker, Daphne S.

AU - Ariens, Lieneke F.M.

AU - Giovannone, Barbara

AU - Hijnen, Dirk Jan

AU - Delemarre, Eveline M.

AU - Knol, Edward

AU - Nierkens, Stefan

AU - de Bruin-Weller, Marjolein S.

AU - Thijs, Judith L.

AU - Drylewicz, Julia

N1 - Funding Information: Dr Bakker reports personal fees from Sanofi Genzyme, outside the submitted work. Dr Hijnen reports grants and personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Incyte, personal fees from Sanofi/Genzyme, grants from Thermo Fisher and personal fees from Pfizer, outside the submitted work. Dr de Bruin‐Weller reports grants as Advisory Board Member/consultant AbbVie, grants as Advisory Board Member/consultant Pfizer, grants as Advisory Board Member/consultant Sanofi Genzyme, grants as Advisory Board Member UCB, grants as Advisory Board Member/consultant Eli Lilly, grants as Advisory Board Member/consultant Regeneron, grants as Advisory Board Member Galderma, grants as PI multicenter studies AbbVie, grants as PI multicenter studies Pfizer, grants as PI multicenter studies Galderma, outside the submitted work. Dr Thijs reports personal fees from Sanofi Genzyme, outside the submitted work. All other authors have nothing to disclose.

PY - 2020/12

Y1 - 2020/12

KW - atopic dermatitis

KW - biologics

KW - biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85088387626&partnerID=8YFLogxK

U2 - 10.1111/all.14492

DO - 10.1111/all.14492

M3 - Letter

C2 - 33305359

AN - SCOPUS:85088387626

SN - 0105-4538

VL - 75

SP - 3287

EP - 3289

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 12

ER -